Abstract
Radionuclide therapy is one of the fields of nuclear medicine and it uses a tumor-specific antibody or peptide that labeled with charged-particle（α particle, β－particle, Auger electron) emitted radionuclide for treatment of tumors. Among those radiations, α particle has been paid attention to clinical application owing to its short path length in tissue and high liner-energy-transfer (LET). There are several promising alpha-emitting radionuclides such as 211At, 212Bi, 212Pb, 223Ra, 227Th, 213Bi and 225Ac. Among them, 225Ac labeled peptide, 225Ac-PSMA-617 has shown the most encouraging outcomes including complete remission of metastasized prostate cancer of patients. However, in order to understand the therapeutic effect of the 225Ac which acts as an in vivo generator and applies to the other cancer treatment, we need to know the physical and chemical properties of the parent and its daughter nuclides to control in vivo.
